New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults, alongside a newly developed companion guideline focused specifically on juvenile axial spondyloarthritis.
Dr. John Cush RheumNow
3 months ago
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
https://t.co/6uLv16aOcX https://t.co/a3NxMdnI9F
Dr. John Cush RheumNow
3 months ago
RHEUMATOLOGIST POLL> ?How valuable is a Lupus Nephritis Indication when treating NON-RENAL lupus? Answer here>> https://t.co/K4aikzZRmY https://t.co/60wM3XJE8n
Dr. John Cush RheumNow
3 months ago
No Fetal Risks with First Trimester NSAID Use
PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital https://t.co/ZVUOizbcdg
Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses.
Dr. John Cush RheumNow
3 months ago
Steroids in SpA? DBRPCT of 94 (nonPsA) SpA pts w/ peripheral arthritis (SJC ≥ 2) placebo or steroids (GC) (csDMARDs background allowed). 76% male, age 32 yrs, TJC 10, SJC 3.6. Wk 24 there was no signif diff betw groups for ACR 50, ACR70 or PSpARC outcomes. https://t.co/snJovW31Uk
Dr. John Cush RheumNow
3 months ago
Retrospective study of 116 BL KOA (Kellgren–Lawrence I–II) pts rx w/ three PRP injx (n 58) or NSAIDs +/- IAhyaluronic acid (n 58). After 5 yrs there was no signif. difference in VAS, WOMAC, and SF-36, with both groups worsening. https://t.co/KDSMTvEl59 https://t.co/lgHOsppIU3
Dr. John Cush RheumNow
3 months ago
Mentors & Mentees can do great things!!! https://t.co/gdf5laCuCm
Dr. John Cush RheumNow
3 months ago
Chinese study of 341 RA pts, half managed post D/C w/ nurse led AI interactive platform vs usual care. @ 6 mos AI platform group had signif better outcomes - DAS28 (-0.77 vs -0.27), HAQ functional status, medication adherence (90 vs 80%), and pt satisfaction (96 vs 76%) https://t.co/SrDgUuAWB3
Dr. John Cush RheumNow
3 months ago
Korean insurance claims study of 50 600 adults w/ newly dx #RA - Persistent low-income significantly increased mortality risk, especially if RA <65 yrs or rural residence; Sustained high-income status provided a protective effect across all age group https://t.co/OIhvz489Ar https://t.co/lYwgc2Ty3n
Dr. John Cush RheumNow
3 months ago
JAMA Review on Low Back Pain
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/liEitQ2ACf
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
